๐ŸŽ Black Friday: 50% off Unlimited and 30% off Pro annual plans
Intuitive Surgical, Inc. (ISRG)
NASDAQ: ISRG ยท Real-Time Price ยท USD
399.05
-8.19 (-2.01%)
At close: Nov 20, 2026, 4:00 PM EST
400.06
+1.01 (0.25%)
After-hours: Nov 20, 2026, 7:59 PM EST

Intuitive Surgical Earnings Call Transcripts

Fiscal Year 2026

  • Q3 revenue rose 22% and procedures grew 15%, supported by broad system placements and growth across da Vinci and Ion. FY2026 da Vinci procedure growth guidance narrowed to 14%-15%; upcoming pricing actions are expected to reduce I&A revenue per procedure 3%-5% at constant mix once fully implemented.

  • Global procedure growth remains a priority, with innovation and new programs like Extended Use Instruments aimed at stimulating growth, especially in cost-sensitive markets. Capital equipment placements are strong, competition is intensifying, and AI-driven digital offerings are gaining traction. Financial performance is robust, exceeding long-term averages.

  • Q2 delivered strong revenue and procedure growth, driven by robust adoption of da Vinci 5, SP, and Ion platforms. Guidance for 2026 remains positive, with continued innovation, stable capital demand, and expanding access in cost-sensitive markets.

  • AGM 2026

    The meeting saw all board nominees elected and all proposals approved, including executive compensation and auditor ratification. Strong financial results were reported for 2025 and Q1 2026, with continued focus on global expansion, innovation, and manufacturing optimization amid competitive and geopolitical challenges.

  • Q1 2026 delivered strong 17% procedure growth and 23% revenue growth, led by robust adoption of da Vinci 5, Ion, and SP platforms, with notable expansion in the U.S. and Europe. Guidance for full-year procedure growth and gross margin was raised, while ongoing challenges persist in China and Japan.

  • Achieved record 2025 results with 3.2 million procedures, strong global expansion, and a successful da Vinci 5 launch. Focus remains on digital innovation, AI integration, and expanding minimally invasive procedures worldwide, with 2026 guidance targeting 13%-15% procedure growth.

Fiscal Year 2025

Fiscal Year 2024

Fiscal Year 2023

Fiscal Year 2022

Fiscal Year 2021

Fiscal Year 2020

Fiscal Year 2019

Fiscal Year 2018

Fiscal Year 2017

Fiscal Year 2016

Fiscal Year 2015

Fiscal Year 2014

Fiscal Year 2013

Fiscal Year 2012

Fiscal Year 2011

Fiscal Year 2010